Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 5;25(5):205. doi: 10.3892/ol.2023.13791

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Tian et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — OS and LRFS of patients in different clinicopathological subgroups according to the use of PORT after propensity score-matching. (A) OS curves for patients with multiple N2 stations. The 5-year OS rate was 49.3% for the PORT group and 27.5% for the non-PORT group. (B) OS curves for patients with N2 PLNs (≥4). The 5-year OS rate was 44.6% for the PORT group and 23.0% for the non-PORT group. (C) OS curves for patients with SCC. The 5-year OS rate was 66.7% for the PORT group and 26.7% for the non-PORT group. (D) LRFS curves for patients with multiple N2 stations. The 5-year LRFS rate was 48.7% for the PORT group and 22.0% for the non-PORT group. (E) LRFS curves for patients with N2 PLNs (≥4). The 5-year LRFS rate was 43.8% for the PORT group and 17.2% for the non-PORT group. (F) LRFS curves for patients with SCC. The 5-year LRFS rate was 66.7% for the PORT group and 16.7% for the non-PORT group. (G) OS curves for patients with pneumonectomy. The 5-year OS rate was 50.0% for the PORT group and 0% for the non-PORT group. LRFS, local recurrence-free survival; OS, overall survival; PLNs, positive lymph nodes; PORT, postoperative radiotherapy; SCC, squamous cell carcinoma.